

CHAPTER ONE: INTRODUCTION.....	1
STUDY GOALS AND OBJECTIVES.....	1
REASONS FOR DOING THE STUDY	1
SCOPE OF REPORT	2
INTENDED AUDIENCE.....	3
METHODOLOGY AND INFORMATION SOURCES.....	3
ANALYST CREDENTIALS.....	4
RELATED BCC REPORTS	4
BCC ONLINE SERVICES.....	4
DISCLAIMER	5
 CHAPTER TWO: SUMMARY.....	 6
<i>SUMMARY TABLE TOTAL EMERGING GEOGRAPHIC MARKETS, BY REGION, THROUGH 2015 (\$ MILLIONS)</i>	 6
<i>SUMMARY FIGURE TOTAL EMERGING GEOGRAPHIC MARKETS, BY REGION, 2007-2015 (\$ MILLIONS)</i>	 7
SUMMARY (CONTINUED).....	8
 CHAPTER THREE: OVERVIEW	 9
OVERVIEW.....	9
<i>TABLE 1 ECONOMIC STATISTICS AND GROSS DOMESTIC PRODUCTION FOR EMERGING COUNTRIES, 2008 (\$ BILLIONS/%)</i>	 10
OVERVIEW (CONTINUED)	11
EMERGING MARKET OPPORTUNITIES	12
EMERGING MARKET CHALLENGES.....	12
Emerging Market Challenges (Continued).....	13
 CHAPTER FOUR: INDIA	 14
MAJOR TRENDS INFLUENCING GROWTH AND EXPANSION.....	14
<i>TABLE 2 SOME FACTS ABOUT INDIA</i>	14
<i>TABLE 3 ECONOMIC STATISTICAL SUMMARY FOR INDIA, 2009</i>	15
<i>TABLE 4 DEMOGRAPHIC STATISTICAL SUMMARY FOR INDIA, 2009</i>	15
PHARMACEUTICAL MARKETS	15
<i>TABLE 5 INDIAN MARKETS BY THERAPEUTIC AREA, THROUGH 2010 (\$ MILLIONS)</i>	 16
BIOLOGICS UPTAKE DRIVEN BY MANUFACTURING ADVANTAGES	16
COMPETITIVE POSITIONING OF INDIA AS EMERGING MARKET	17
GENERICS PRODUCTS AND COMPANIES CONTINUE TO THRIVE IN INDIA	17
<i>TABLE 6 SUMMARY OF APPROVED ACTIVE PHARMACEUTICAL INGREDIENTS (API) IN INDIA, 2009</i>	 18

COMPETITIVE POSITIONING OF THE TOP 10 PLAYERS.....	18
GROWING ALLIANCES IN BIOPHARMACEUTICALS.....	19
<i>TABLE 7 KEY LICENSING AND PARTNERSHIP DEALS IN INDIA, 2007–2010.....</i>	<i>19</i>
JAPANESE ACCESSING INDIA FOR GENERICS SHARE	20
PHARMACEUTICAL REGULATORY DYNAMICS, REGULATIONS, AND LAWS	20
<i>TABLE 8 INDIA PUBLIC INVESTMENT INTO HEALTHCARE (% OF GDP), 1950-2010</i>	<i>21</i>
LEADING THERAPEUTIC SEGMENTS OUTLOOK.....	21
<i>TABLE 9 INDIAN THERAPEUTIC MARKET FORECAST, THROUGH 2015 (\$ MILLIONS).....</i>	<i>21</i>
LEADING REGIONAL PRODUCTS	22
<i>TABLE 10 LEADING PRODUCTS IN INDIA, THROUGH 2010 (\$ MILLIONS).....</i>	<i>22</i>
INTELLECTUAL PROPERTY.....	23
SUMMARY	23
INDIA’S ADOPTION OF PRODUCT PATENT REGIME	23
<i>TABLE 11 TOP 10 INDIAN COMPANIES THROUGH 2010 (\$ MILLIONS/%).....</i>	<i>24</i>
CIPLA.....	24
CIPLA THERAPEUTIC FOCUS	25
CIPLA RESEARCH AND DEVELOPMENT	25
RANBAXY	25
RANBAXY THERAPEUTIC FOCUS	26
RESEARCH AND DEVELOPMENT	26
GSK-INDIA	26
THERAPEUTIC FOCUS	27
RESEARCH AND DEVELOPMENT	27
PIRAMAL HEALTHCARE.....	27
THERAPEUTIC FOCUS	27
RESEARCH AND DEVELOPMENT	28
ZYDUS CADILA	28
THERAPEUTIC FOCUS	28
RESEARCH AND DEVELOPMENT	28
SUN PHARMACEUTICAL	29
THERAPEUTIC FOCUS	29
RESEARCH AND DEVELOPMENT	29
LUPIN	30
THERAPEUTIC FOCUS	30
RESEARCH AND DEVELOPMENT	30
ALKEM.....	30
THERAPEUTIC FOCUS	31
RESEARCH AND DEVELOPMENT	31

SANOFI-AVENTIS: INDIA	31
THERAPEUTIC FOCUS	32
RESEARCH AND DEVELOPMENT	32
MANKIND.....	32
THERAPEUTIC FOCUS	32
RESEARCH AND DEVELOPMENT	32
CHAPTER FIVE: EASTERN EUROPE	33
MAJOR TRENDS INFLUENCING GROWTH AND EXPANSION.....	33
PHARMACEUTICAL REGULATORY DYNAMICS, REGULATIONS, AND LAWS	33
<i>TABLE 12 SELECTED M&A TRANSACTIONS IN EASTERN EUROPE BETWEEN 2007 AND 2009</i>	<i>34</i>
LEADING THERAPEUTIC SEGMENTS	34
BIOSIMILARS YIELD OPPORTUNITY	34
ONCOLOGY OF PARTICULAR INTEREST.....	35
<i>TABLE 13 TOP 10 PLAYERS IN THE EASTERN EUROPEAN THERAPEUTIC MARKETS, THROUGH 2010 (\$ MILLIONS)</i>	<i>36</i>
NOVARTIS.....	36
SANOFI-AVENTIS	37
GSK.....	37
SERVIER.....	37
ROCHE.....	38
BAYER.....	38
PFIZER.....	39
TEVA	39
ZENTIVA.....	40
KRKA.....	40
<i>TABLE 14 EASTERN EUROPEAN THERAPEUTIC MARKET FORECAST, THROUGH 2015 (\$ MILLIONS/%)</i>	<i>41</i>
CHAPTER SIX: LATIN AMERICA	42
MAJOR TRENDS INFLUENCING GROWTH AND EXPANSION.....	42
<i>TABLE 15 ECONOMIC STATISTICS OF LATIN AMERICA, 2008 (\$ BILLIONS).....</i>	<i>42</i>
<i>TABLE 16 DEMOGRAPHIC PROFILE OF LATIN AMERICAN COUNTRIES, 2009.....</i>	<i>43</i>
<i>TABLE 17 SNAPSHOT OF HEALTHCARE STATISTICS IN LATIN AMERICA, 2009.....</i>	<i>43</i>
<i>TABLE 18 LATIN AMERICAN MARKETS BY COUNTRY, 2007–2010 (\$ MILLIONS/%).....</i>	<i>44</i>
<i>TABLE 19 HEALTHCARE DELIVERY STATISTICS IN LATIN AMERICA, 2009.....</i>	<i>44</i>
PHARMACEUTICAL REGULATORY DYNAMICS, REGULATIONS, AND LAW	45

<i>TABLE 20 LATIN AMERICAN COUNTRY WATCH LIST, AS PER PHRMA, 2009.....</i>	<i>46</i>
BIOSIMILAR REGULATORY PATHWAY IN LATIN AMERICA.....	47
LEADING THERAPEUTIC SEGMENTS AND PRODUCTS.....	47
<i>TABLE 21 LATIN AMERICAN MARKETS BY THERAPEUTIC AREA, THROUGH 2010 (\$ MILLIONS/%)</i>	<i>47</i>
BRAZIL.....	47
MEXICO	48
NME LAUNCHES IN MEXICO, 2008	49
VENEZUELA.....	49
ARGENTINA.....	50
COLOMBIA.....	51
CHILE	51
<i>TABLE 22 LATIN AMERICAN THERAPEUTIC MARKET FORECAST, THROUGH 2015 (\$ MILLIONS/%)</i>	<i>52</i>
INTELLECTUAL PROPERTY.....	53
BRAZIL.....	53
MEXICO	53
VENEZUELA	54
ARGENTINA.....	54
<i>TABLE 23 TOP 10 PLAYERS IN THE LATIN AMERICAN MARKETS, THROUGH 2010 (\$ MILLIONS/%)</i>	<i>54</i>
SANOFI-AVENTIS	55
NOVARTIS	55
BAYER.....	56
PFIZER.....	56
EMS.....	57
MERCK (SCHERING PLOUGH).....	57
BOEHRINGER INGELHEIM	57
JOHNSON & JOHNSON	58
GSK.....	58
ROCHE.....	59
CHAPTER SEVEN: MIDDLE EAST.....	60
MAJOR TRENDS INFLUENCING GROWTH AND EXPANSION.....	60
<i>TABLE 24 ECONOMIC STATISTICAL SUMMARY FOR MIDDLE EAST, 2009</i>	<i>60</i>
<i>TABLE 25 DEMOGRAPHIC STATISTICAL SUMMARY FOR MIDDLE EAST, 2009.....</i>	<i>61</i>
PHARMACEUTICAL REGULATORY DYNAMICS, REGULATIONS, AND LAWS	61
<i>TABLE 26 MIDDLE EAST MARKETS BY COUNTRY. THROUGH 2010 (\$ MILLIONS/%).....</i>	<i>62</i>
EGYPT.....	62
Summary.....	62

Drug Pricing and Reimbursement	63
TURKEY.....	64
Summary.....	64
Drug Pricing and Reimbursement	64
<i>TABLE 27 TURKISH HEALTHCARE REIMBURSEMENT COVERAGE</i>	
<i>BY DESIGNATION</i>	<i>65</i>
SAUDI ARABIA	66
Summary.....	66
Drug Pricing and Reimbursement	66
Drug Pricing ... (Continued)	67
ISRAEL	68
Summary.....	68
Drug Pricing and Reimbursement	68
JORDAN	69
Summary.....	69
Drug Pricing and Reimbursement	70
UNITED ARAB EMIRATES.....	70
Summary.....	70
Drug Pricing and Reimbursement	71
LEBANON.....	71
Summary.....	71
Drug Pricing and Reimbursement	72
KUWAIT	73
Summary.....	73
Drug Pricing and Reimbursement	73
LEADING THERAPEUTIC SEGMENTS	74
<i>TABLE 28 MIDDLE EAST MARKETS BY THERAPEUTIC AREA,</i>	
<i>THROUGH 2010 (\$ MILLIONS/%)</i>	<i>74</i>
LEADING REGIONAL PRODUCTS	74
SERETIDE (GSK)	75
LIPITOR (PFIZER)	75
AUGMENTIN (GSK/MUP)	75
GLIVEC (NOVARTIS)	75
DIOVAN/CO-DIOVAN (NOVARTIS)	76
SPIRIVA (BOEHRINGER INGELHEIM).....	76
PLAVIX (SANOFI-AVENTIS)	76
CIPRALEX (LUNDBECK).....	77
<i>TABLE 29 MIDDLE EAST THERAPEUTIC MARKET FORECAST,</i>	
<i>THROUGH 2015 (\$ MILLIONS/%)</i>	<i>78</i>
INTELLECTUAL PROPERTY.....	78
SAUDI ARABIA	78
EGYPT	79
TURKEY.....	79
ISRAEL.....	80

JORDAN.....	80
UNITED ARAB EMIRATES.....	81
LEBANON.....	82
KUWAIT.....	82
<i>TABLE 30 TOP 10 PLAYERS IN THE MIDDLE EAST MARKETS, THROUGH 2010 (\$ MILLIONS/%)</i>	83
NOVARTIS.....	83
GSK.....	84
SANOFI-AVENTIS.....	85
PFIZER.....	85
CHAPTER EIGHT: RUSSIA.....	86
MAJOR TRENDS INFLUENCING GROWTH AND EXPANSION.....	86
<i>TABLE 31 ECONOMIC STATISTICAL SUMMARY FOR RUSSIA, 2009</i>	86
<i>TABLE 32 DEMOGRAPHIC STATISTICAL SUMMARY FOR RUSSIA, 2009</i>	87
PHARMACEUTICAL REGULATORY DYNAMICS, REGULATIONS, AND LAWS.....	87
DRUG PRICES AND REIMBURSEMENT.....	87
Drug Prices and ... (Continued).....	88
HEALTHCARE REFORM IN RUSSIA.....	89
LEADING THERAPEUTIC SEGMENTS.....	90
<i>TABLE 33 RUSSIA MARKETS BY THERAPEUTIC AREA, THROUGH 2010 (\$ MILLIONS/%)</i>	90
<i>TABLE 34 RUSSIA'S THERAPEUTIC MARKET FORECAST, THROUGH 2015 (\$ MILLIONS/%)</i>	91
LEADING REGIONAL PRODUCTS.....	91
ACTOVEGIN: NYCOMED.....	91
ARBIDOL: PHARMSTANDARD.....	92
MERONEM: ASTRAZENECA.....	92
ESSENTIALE FORTE N: SANOFI-AVENTIS.....	92
VIAGRA: PFIZER.....	93
LINEX: NOVARTIS.....	93
MEXIDOL: FARMASOFT.....	93
AMOKSIKLAV: NOVARTIS.....	93
HEPTRAL: HOSPIRA.....	94
MILDRONAT: GRINDEX.....	94
INTELLECTUAL PROPERTY.....	94
<i>TABLE 35 TOP 10 PLAYERS IN THE RUSSIAN MARKETS, THROUGH 2010 (\$ MILLIONS/%)</i>	95
NOVARTIS.....	95
SANOFI-AVENTIS.....	95
SERVIER.....	96
BAYER.....	96
PHARMSTANDARD.....	97

GEDEON RICHTER	97
Gedeon Richter (Continued).....	98
CHAPTER NINE: SOUTH KOREA.....	99
MAJOR TRENDS INFLUENCING GROWTH AND EXPANSION.....	99
PHARMACEUTICAL REGULATORY DYNAMICS, REGULATIONS, AND LAWS	99
PHARMACEUTICAL REGULATORY DYNAMICS, REGULATIONS, AND LAWS	100
HEALTHCARE EXPENSES	101
HEALTHCARE REFORMS	102
LEADING THERAPEUTIC SEGMENTS AND PRODUCTS.....	103
<i>TABLE 36 SOUTH KOREA MARKETS BY THERAPEUTIC AREA, THROUGH 2010 (\$ MILLIONS/%)</i>	103
<i>TABLE 36 (CONTINUED)</i>	104
GASTROINTESTINAL.....	104
CARDIOVASCULAR	104
INFECTIOUS DISEASES	105
CENTRAL NERVOUS SYSTEM.....	105
<i>TABLE 37 SOUTH KOREA THERAPEUTIC MARKET FORECAST, THROUGH 2015 (\$ MILLIONS/%)</i>	106
INTELLECTUAL PROPERTY.....	106
<i>TABLE 38 TOP 10 PLAYERS OF THE SOUTH KOREAN MARKETS, THROUGH 2010 (\$ MILLIONS/%)</i>	107
DONG-A.....	108
SANOFI-AVENTIS	108
DAEWOONG.....	109
HANMI	109
PFIZER.....	110
CHAPTER TEN: SOUTH AFRICA.....	111
MAJOR TRENDS INFLUENCING GROWTH AND EXPANSION.....	111
<i>TABLE 39 DEMOGRAPHIC STATISTICAL SUMMARY OF SOUTH AFRICA, 2009</i>	112
<i>TABLE 40 ECONOMIC STATISTICAL SUMMARY OF SOUTH AFRICA, 2009</i>	112
PHARMACEUTICAL REGULATORY DYNAMICS, REGULATIONS, AND LAWS	113
PHARMACEUTICAL REGULATORY (CONTINUED)	114
SECOND SOUTH AFRICAN GOVERNMENT ARV TENDER	115
RISING TRIAL REGISTRATIONS.....	115
INCREASING GENERICS UPTAKE	116
LEADING THERAPEUTIC SEGMENTS AND PRODUCTS.....	116
<i>TABLE 41 SOUTH AFRICA MARKETS BY THERAPEUTIC AREA, THROUGH 2010 (\$ MILLIONS/%)</i>	117

<i>TABLE 42 SOUTH AFRICA THERAPEUTIC MARKET FORECAST, THROUGH 2015 (\$ MILLIONS/%)</i>	118
INTELLECTUAL PROPERTY	118
FURTHER FOCUS AROUND PATENT POOLING FOR HIV/AIDS THERAPIES	119
TOP 10 PLAYERS: SUMMARY	120
<i>TABLE 43 SOUTH AFRICA MARKETS BY COMPANY, THROUGH 2010 (\$ MILLIONS/%)</i>	121
ASPEN.....	121
ADCOCK INGRAM.....	121
SANOFI-AVENTIS	122
NOVARTIS	122
PFIZER	122
CIPLA MEDPRO	122
<i>TABLE 44 SOUTH AFRICA MARKET FORECAST BY COMPANY, THROUGH 2015 (\$ MILLIONS)</i>	123
CHAPTER ELEVEN: CHINA.....	124
MAJOR TRENDS INFLUENCING GROWTH AND EXPANSION.....	124
MAJOR TRENDS INFLUENCING ... (CONTINUED)	125
PHARMACEUTICAL REGULATORY DYNAMICS, REGULATIONS, AND LAWS	126
PUBLIC SECTOR INSURANCE.....	126
RURAL AREA INSURANCE AND REIMBURSEMENT	127
PRIVATE SECTOR REIMBURSEMENT	127
<i>TABLE 45 EXPECTED PATENT EXPIRATIONS IN CHINA FOR KEY THERAPEUTICS, AS OF 2009</i>	128
GENERAL REIMBURSEMENT SYSTEM	128
PRICING MECHANISM.....	128
OUTLOOK FOR REIMBURSEMENT IN CHINA	129
LEADING THERAPEUTIC SEGMENTS AND PRODUCTS.....	130
INTELLECTUAL PROPERTY.....	131
KEY PLAYERS: SUMMARY	132
PFIZER	132
<i>TABLE 46 CHINA'S MARKETS BY THERAPEUTIC AREA, THROUGH 2010 (\$ MILLIONS)</i>	132
<i>TABLE 47 CHINA'S THERAPEUTIC MARKET FORECAST, THROUGH 2015 (\$ MILLIONS/%)</i>	133
ASTRAZENECA.....	133
BAYER	134
ROCHE	135